Abstract
The OAT trial1 was a key investigation, contributing to contemporary practice in the treatment of acute myocardial infarction (AMI). It unexpectedly demonstrated that for patients undergoing angiography between 3 and 28 days after AMI with poor or absent flow in a major infarct-related artery (IRA), re-establishing flow by percutaneous coronary intervention (PCI) provided no benefit, with indeed the suggestion of harm. There were some caveats to this statement, based on the specific population studied: the patients were a high-risk group, in that the lesion had to be in a proximal vessel, or there had to be an ejection fraction (EF) of <50%. The patients were also those about which little information was previously available regarding optimum treatment: the subtended myocardium had to be either dyskinetic or akinetic, or, if the myocardium was hypokinetic or normal, then mild or moderate (but not severe) ischaemia had to be present.